17,261 trials
Moderate or Severe Submental Fullness
Primary: Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores — -0.7; -0.8; -0.4 units on a scale — p=0.052
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events — 20; 19; 22; 21 participants
Opioid Induced Constipation (OIC)
Primary: Change From Baseline in Spontaneous Bowel Movements (SBMs) Per Week During Week 1 — 1.8; 2.6; 1.9; 3.6 Number of SBMs/week — p=0.7781
Hereditary Angioedema (HAE)
Primary: Normalized Number of Angioedema Attacks During the Treatment Period — 1.58; 0.97 angioedema attacks — p=0.0523
Glioblastoma Multiforme
Primary: Progression Free Survival PPX/RT Versus TMZ/RT for Patients With GBM Without Methylation — 31; 15 participants
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Solid Cancers
Primary: Percentage of Participants Who Experienced an Adverse Event — 33.3 percentage of participants
Healthy · Amyotrophic Lateral Sclerosis · Neuromuscular Disease
Primary: Accuracy of Typing With BCI Keyboard. — 85; 83; 83 percentage accuracy
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Melanoma
Primary: Percentage of Participants Surviving at 1 Year — 66.7 Percentage of participants
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants
Dental Pain
Primary: Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10) — 5.745; 30.986 units on a scale — p=<0.001
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Progression-free Survival — 2.6; 2.9 months
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Restless Legs Syndrome
Primary: Mean Change From Baseline to Day 84 for International Restless Leg Syndrome Study Group (IRLSSG) Scale — -2.4; -14.3; -16.0 units on a scale